about
Switching treatments in COPD: implications for costs and treatment adherenceThe association of weight with the detection of airflow obstruction and inhaled treatment among patients with a clinical diagnosis of COPDAdherence to prescribed treatment for asthma: evidence from pharmacy benefits data.How to report and discuss ADME data in medicinal chemistry publications: in vitro data or in vivo extrapolations?Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management.Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronic obstructive pulmonary disease.Patient adherence in COPD.Managing patient adherence and quality of life in epilepsy.Activities of life: the COPD patient.Customizing inhaled therapy to meet the needs of COPD patients.Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol.Factors to consider when selecting a nebulizer for a new inhaled drug product development program.Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit?The influence of type of inhalation device on adherence of COPD patients to inhaled medication.Clinical efficacy and safety of the combination of ipratropium bromide and fenoterol inhaled via the Respimat Soft Mist inhaler for relief of airflow obstruction.Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related.Insurance status and patient behavior with asthma medications.Medication compliance and asthma: overlooking the trees because of the forest.Differences in Adherence to Common Inhaled Medications in COPD.Efficacy and safety of a multifactor intervention to improve therapeutic adherence in patients with chronic obstructive pulmonary disease (COPD): protocol for the ICEPOC study.Once-daily fluticasone propionate in stable asthma: study on airway inflammation.Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)
P2860
Q26776324-843E658E-CC5D-46D9-B4E1-2231863CF188Q27349146-05365D73-449E-415B-9E15-28341D0B6807Q30786484-A74CE93C-5B97-4834-B571-3A65276BC392Q30920065-C6300019-964D-4D0F-B865-4A33858577CFQ34523871-CF86BF38-FFEA-43E6-8200-2066FE5DE13AQ34621079-B5F67F2A-559D-467E-A70E-7F59A78BE1B7Q36562432-438C180D-58CF-4324-85D7-E2307C3C8AF8Q37125509-4B9A1330-170F-40D4-A160-A3C49DC87448Q37610454-B75B7121-D18A-4A82-AC99-71C7D5AA5B41Q37702735-3C611B24-B736-45BD-A679-6267502E174AQ38352425-E826260F-2274-4C3A-82F5-14A2BF8366F7Q38373085-99346788-6827-4F66-A294-F3D9382C6213Q38630770-D3CFFB84-FCE4-43BE-AE89-79F556ADF375Q38932081-E85F338E-EA18-4614-B93A-2BC76C491AB3Q39324466-087998D9-7C70-4D91-B7CC-B5D652D19573Q39459241-ADC2D07D-A557-4AC6-A372-A78913F44D4CQ39669585-661795C9-47AB-427A-863E-67FBE2D10AFBQ41033346-4EB98ED2-8AC6-4382-836E-D12EAD01D17DQ41211645-89266CFF-1DAB-4399-B7D0-0D46FEF4103AQ41878463-6ED6CF9D-E72F-4C33-858D-A6D1EF5CE925Q46975776-E5A470E6-E16C-4B5E-B246-807ADC9F4B6EQ57809552-5DD92AD6-33C9-4D69-94D7-6062A194F97A
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Multiple dose regimens. Impact on compliance.
@en
type
label
Multiple dose regimens. Impact on compliance.
@en
prefLabel
Multiple dose regimens. Impact on compliance.
@en
P1433
P1476
Multiple dose regimens. Impact on compliance.
@en
P2093
Tashkin DP
P304
P356
10.1378/CHEST.107.5_SUPPLEMENT.176S
P407
P433
P577
1995-05-01T00:00:00Z